Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
A Jonášová, R Neuwirtová, J Čermák… - British Journal of …, 1998 - Wiley Online Library
We report 17 cytopenic patients with myelodysplastic syndrome (MDS) of refractory anaemia
(RA) subtype with hyper‐, normo‐ or hypo‐cellular bone marrow (BM), who were treated …
(RA) subtype with hyper‐, normo‐ or hypo‐cellular bone marrow (BM), who were treated …
[PDF][PDF] Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del (5q) myelodysplastic syndromes …
…, A Giagounidis, S Gröpper, A Jonasova… - Journal of Clinical …, 2016 - researchgate.net
Purpose This international phase III, randomized, placebo-controlled, double-blind study
assessed the efficacy and safety of lenalidomide in RBC transfusion–dependent patients with …
assessed the efficacy and safety of lenalidomide in RBC transfusion–dependent patients with …
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes …
…, RS Komrokji, J Shortt, D Valcarcel, A Jonasova… - The Lancet, 2023 - thelancet.com
Background Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for
anaemia in most patients with lower-risk myelodysplastic syndromes but responses are …
anaemia in most patients with lower-risk myelodysplastic syndromes but responses are …
Epigenetic silencing of the oncogenic miR‐17‐92 cluster during PU. 1‐directed macrophage differentiation
…, J Kokavec, J Rybarova, F Savvulidi, A Jonasova… - The EMBO …, 2011 - embopress.org
The oncogenic cluster miR‐17‐92 encodes seven related microRNAs that regulate cell
proliferation, apoptosis and development. Expression of miR‐17‐92 cluster is decreased upon …
proliferation, apoptosis and development. Expression of miR‐17‐92 cluster is decreased upon …
[HTML][HTML] Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
…, A Almeida, U Platzbecker, A Jonasova… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Treatment options are limited for patients with lower-risk myelodysplastic syndromes
(LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a …
(LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a …
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes
…, G Sanpaolo, A Jonasova… - British journal of …, 2015 - Wiley Online Library
The primary objective of this study was to investigate factors associated with fatigue severity
in newly diagnosed patients with higher‐risk myelodysplastic syndromes ( MDS ). The …
in newly diagnosed patients with higher‐risk myelodysplastic syndromes ( MDS ). The …
[HTML][HTML] TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes
M Belickova, J Vesela, A Jonasova, B Pejsova… - Oncotarget, 2016 - ncbi.nlm.nih.gov
TP53 mutations are frequently detected in patients with higher-risk myelodysplastic syndromes
(MDS); however, the clinical impact of these mutations on the disease course of patients …
(MDS); however, the clinical impact of these mutations on the disease course of patients …
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML
…, DJ DeAngelo, I Galinsky, BM Wolpin, A Jonasova… - Blood, 2004 - ashpublications.org
The FLT3 receptor is activated by juxtamembrane insertion mutations and by activation loop
point mutations in patients with acute myeloid leukemia (AML). In a systematic tyrosine …
point mutations in patients with acute myeloid leukemia (AML). In a systematic tyrosine …
[HTML][HTML] RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS
…, J Mertova, J Soukupova Maaloufova, A Jonasova… - Leukemia, 2022 - nature.com
Patients with lower-risk myelodysplastic syndromes (LR-MDS) have a generally favorable
prognosis; however, a small proportion of cases progress rapidly. This study aimed to define …
prognosis; however, a small proportion of cases progress rapidly. This study aimed to define …
[HTML][HTML] Circulating small noncoding RNAs have specific expression patterns in plasma and extracellular vesicles in myelodysplastic syndromes and are predictive of …
…, J Cermak, T Hrdinova, M Krijt, J Valka, A Jonasova… - Cells, 2020 - mdpi.com
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders with large heterogeneity
at the clinical and molecular levels. As diagnostic procedures shift from bone marrow …
at the clinical and molecular levels. As diagnostic procedures shift from bone marrow …